New consensus multivariate models based on PLS and ANN studies of sigma-1 receptor antagonists

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Pharmacology

Background:

• Neuropathic pain treatment is challenging with limited approved drugs.
• Sigma-1 receptor antagonists show promise for neuropathic pain.
• 1-arylpyrazole derivatives are being investigated for therapeutic potential.

Purpose of the Study:

• To develop quantitative structure-activity relationship (QSAR) models for 1-arylpyrazole derivatives.
• To identify key molecular descriptors for designing novel neuropathic pain therapeutics.
• To apply multivariate statistical methods for drug discovery.

Main Methods:

• Partial Least Square (PLS) regression analysis.
• Artificial Neural Network (ANN) modeling, specifically Multi-Layer Perceptrons (MLP-ANNs).
• Development of consensus models (MLP-ANN-CM and GCM) combining PLS and ANN approaches.

Main Results:

• Validated PLS model with good predictive performance (r²_test = 0.746).
• Developed MLP-ANN consensus model with improved prediction (r²_test = 0.824).
• Achieved a General Consensus Model (GCM) with high predictive accuracy (r²_test = 0.811).
• Identified significant descriptors (GGI6, Mor23m, SRW06, H7m, MLOGP, μ) for 1-arylpyrazole design.

Conclusions:

• Multivariate QSAR models are powerful tools for rational drug design.
• The identified descriptors provide insights for developing new 1-arylpyrazole-based neuropathic pain treatments.
• This approach facilitates the discovery of novel sigma-1 receptor antagonists.